Protocol Ledger

NCT06647953 · Phase III · RECRUITING

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Interventional Phase III clinical trial protocol NCT06647953 sponsored by Children's Oncology Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-21 Enrollment: 110 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06647953
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)110 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06647953
Protocol FieldVerified Registry Value
NCT IdentifierNCT06647953
Consolidated Lead SponsorChildren's Oncology Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment110 participants (ESTIMATED)
Registered Start Date2025-03-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI